These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38483962)

  • 1. Guanfacine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Down Syndrome: A Retrospective Chart Review.
    Powers JH; Wu M; Palumbo M; Keary CJ; McDougle CJ; Ravichandran C; Thom RP
    J Child Adolesc Psychopharmacol; 2024 Mar; 34(2):95-103. PubMed ID: 38483962
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    BMC Psychiatry; 2020 Oct; 20(1):485. PubMed ID: 33008345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
    McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR; Kollins SH; Wigal TL
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanfacine extended-release: in attention deficit hyperactivity disorder.
    Muir VJ; Perry CM
    Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.